510(k) device
EchoGo Heart Failure (2.0)
Ultromics Limited · Adjunctive Heart Failure Status Indicator (QUO, Class II) · First FDA decision Nov 23, 2022, newest Sep 23, 2024Heart failure
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
1
Naming "EchoGo"
MAUDE reports
0
Brand "EchoGo", since 2015
PubMed studies
16
Mentioning "EchoGo"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EchoGo Heart Failure (2.0)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K240013 · Decided Sep 23, 2024 · 265 days after receipt
Device type: Adjunctive Heart Failure Status Indicator (QUO) · Cardiology
- EchoGo Heart FailureBreakthrough510(k)
K222463 · Decided Nov 23, 2022 · 100 days after receipt
Device type: Adjunctive Heart Failure Status Indicator (QUO) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Cardiac Rehabilitation Programs for Chronic Heart FailureNational determinationOn the books20.10.1Updated Sep 24, 2026
- Cardiac Contractility Modulation (CCM) for Heart Failure (HF)National determinationOn the books20.39Updated Sep 24, 2026
- Nesiritide for Treatment of Heart Failure PatientsNational analysisReview closedCAG-00289NUpdated Sep 18, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
- Cardiac Rehabilitation (CR) Programs - Chronic Heart FailureNational analysisReview closedCAG-00437NUpdated Sep 17, 2026
- Cardiac Contractility Modulation (CCM) for Heart FailureNational analysisReview closedCAG-00469NUpdated Sep 17, 2026
- Nesiritide for Treatment of Heart Failure PatientsNational determinationOn the books200.1Updated Oct 2, 2015
Clinical trials
Device studies on ClinicalTrials.gov that name "EchoGo", any status and sponsor, newest update first.
Ultromics LtdNot on our public-company list
NCT04877899 · 250 participants (planned) · Start Oct 8, 2020 · Primary completion Mar 31, 2021
Device: EchoGo · For: Cardiotoxicity; Cancer
Sites: Edmonton, Canada
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EchoGo", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QUO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EchoGo"[tiab]. The summary above synthesizes these.
- Evaluating artificial intelligence-driven stress echocardiography analysis system (EASE study): A mixed method study.
Mahdavi M, Thomas N, Flood C, et al. · BMJ Open · 2024Research Support, Non-U.S. Gov't
- PROTEUS Study: A Prospective Randomized Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiography.
Woodward G, Bajre M, Bhattacharyya S, et al. · Am Heart J · 2023Randomized Controlled Trial, Multicenter Study
- Utility of an Automated Artificial Intelligence Echocardiography Software in Risk Stratification of Hospitalized COVID-19 Patients.
Wang TKM, Cremer PC, Chan N, et al. · Life (Basel) · 2022
- Artificial intelligence calculated global longitudinal strain and left ventricular ejection fraction predicts cardiac events and all-cause mortality in patients with chest pain.
O'Driscoll JM, Tuttolomondo D, Gaibazzi N · Echocardiography · 2023Research Support, Non-U.S. Gov't
- Evaluating the Performance and Potential Bias of Predictive Models for Detection of Transthyretin Cardiac Amyloidosis.
Hourmozdi J, Easton N, Benigeri S, et al. · JACC Adv · 2025
- Evaluating the performance and potential bias of predictive models for detection of transthyretin cardiac amyloidosis.
Hourmozdi J, Easton N, Benigeri S, et al. · medRxiv · 2025Preprint
- Artificial intelligence based left ventricular ejection fraction and global longitudinal strain in cardiac amyloidosis.
Cotella JI, Slivnick JA, Sanderson E, et al. · Echocardiography · 2023
- Alignment Between Cardiologists and AI-Driven Diagnostic Systems: Mixed Methods Study.
Mahdavi M, White S, Hothi SS, et al. · J Med Internet Res · 2026
- Global Longitudinal Strain Is Associated with Mortality in Patients with Multiple Myeloma.
Cui Z, Castagna F, Hanif W, et al. · J Clin Med · 2023
- External validation of artificial intelligence for detection of heart failure with preserved ejection fraction.
Akerman AP, Al-Roub N, Angell-James C, et al. · Nat Commun · 2025Validation Study
- Left ventricular assessment with artificial intelligence increases the diagnostic accuracy of stress echocardiography.
O'Driscoll JM, Hawkes W, Beqiri A, et al. · Eur Heart J Open · 2022
- EchoGO: annotation-context-aware functional interpretation of transcriptomic data.
Escobar-Sierra C, Langschied F, Miller A, et al. · MethodsX · 2026
Other devices of this type
Also filed under product code QUO.
- CardioVisionIcardio.Ai · 510(k) 2025
- Vivio® LVEDP SystemAvicena, LLC · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.